ArticleJournal of clinical immunology2023
Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.
Kevin Rosenbach et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papertrialcites it